N4 Pharma Share Discussion Threads

[pwal] 12/5/2023 10:37

This was from the update:The Company has also established the growth curve of the xenograft tumour model to be used, so once the BCL-2 in vitro work is complete, the Company will be ready to start the in vivo studies, as long as supply of the siRNA is not further interrupted.Anyone know when BCL-2 in vitro work will complete?

[tenniselbow] 26/4/2023 12:12

Turner Pope Did a update paper today
They need to talk to Nobby to understand the results from trials

[nobbygnome] 25/4/2023 20:03

I have one question. Have those pesky Nuvec particles ever been in a human yet? Thought not! Until they have been tested in humans there remains a massive risk here…

[blackhorse23] 25/4/2023 09:44

Sold now & bought HVO

[jakleeds] 25/4/2023 07:19

RNS Number : 2792X

N4 Pharma PLC

25 April 2023

25 April 2023

N4 Pharma Plc

("N4 Pharma" or the "Company")

siRNA update

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec(R), a novel delivery system for cancer treatments and vaccines, is pleased to provide a further update on its ongoing in vitro siRNA research work.

BCL-2 assay has been established

Further to the announcement on 18 April 2023, the Company has now completed work on establishing assays to measure how Nuvec(R) loaded with BCL-2 siRNA can silence expression of the BCL-2 protein. BCL-2 is a form of protein that regulates cell death in healthy cells however aberrant expression can facilitate tumour development and resistance to cancer therapy.

Testing underway to generate dose response curve for BCL-2 studies

This means that the Company can now proceed to generate a dose response curve for knockdown of BCL-2 expression to compliment the one already generated for EGFR (epidermal growth factor receptor). EGFR is found on the surface of some normal cells and is involved in cell growth. It may also be found at high levels on some types of cancer cells, which causes these cells to grow and divide.

In vitro studies indicate similar inhibition profile to two commercial therapies

Further in vitro studies have demonstrated that the maximum inhibition of cell growth by SiRNA to either EGFR or BCL-2 loaded on Nuvec(R) was comparable to that produced by two commercially available small molecule drugs, Gefitinib for EGFR and Venetoclax for BCL-2.

Gefitinib: (sold in Europe and Asia) is a type of targeted small molecule cancer drug called a tyrosine kinase inhibitor (TKI) . Tyrosine kinases are proteins that send signals telling cancer cells to grow. Gefitinib blocks these signals. For Gefitinib to work the cancer cells need to have receptors for EGFR.

Venetoclax: sold under the brand names Venclexta and Venclyxto, is a type of targeted therapy drug called a BCL-2 inhibitor (blocker)used to treat adults with chronic lymphocytic leukaemia, small lymphocytic lymphoma, or acute myeloid leukaemia. Some leukaemia or cancer cells make too much of the BCL-2 protein.

Next steps

Further work is planned to assess the minimal loading of siRNA on Nuvec(R) to achieve comparable inhibition to the two commercially available drugs. The next step in the in vitro research work is to undertake a full dose response curve study for siRNA loaded Nuvec(R) and compare to the dose response curve for Gefitinib and Venetoclax.

Nigel Theobald, Chief Executive Officer of the Company, commented:

"We are very pleased with these in vitro results for Nuvec(R) loaded with EGFR and BCL-2, which show that the first investigated dose produces comparable cellular apoptosis to two commercially available products.

"We also now have the assay established to complete the dose response expression work for BCL-2, but we already know that BCL-2 must be expressed, as the cell apoptosis work has shown that it knocks down the gene to produce cell death."

[pwal] 20/4/2023 12:24

The Company has also established the growth curve of the xenograft tumour model to be used, so once the BCL-2 in vitro work is complete, the Company will be ready to start the in vivo studiesSo, when is the BCL-2 work likely to complete?

[pwal] 13/4/2023 10:23

So what is the size of the cancer care industry?explaining why Nuvec®'s unique high loading capacity, for both small and large plasmids, makes it well-suited for the delivery of a variety of oncotherapeutics.

[pwal] 14/2/2023 15:04

Some volume today. Any reason?

[volsung] 15/1/2023 11:33

Pharma is sick

[vaston] 28/11/2022 13:44

check the company out.

[sankshiela] 18/11/2022 12:14

BLACKHORSE IS A VIRUS
EVERYTGING IT TOUCHES IS DESTROYED

[blackhorse23] 18/11/2022 12:09

Bought MCL (LSE) today , Friday deal lol

[scepticalinvestor] 18/11/2022 10:21

Yet another bargepole AIM lifestyle stock.

[goforgold1] 18/11/2022 09:53

Fuvking hell Turner Pope . The cowboys of AIM . This share is doomed it's either TP or Death Spiral Loan . Wow Another con full of them at moment . Never buy a share from were TP involved your lose everything

[nobbygnome] 18/11/2022 09:48

Wow, bid below the placing price!

[amaretto1] 18/11/2022 07:28

Turner Pope strikes again !!

[nobbygnome] 18/11/2022 07:15

Ouch. Further massive dilution at a very low price!

[amanitaangelicus] 16/11/2022 07:25

Rns ...Primary goals not achieved. Divn bother ...errrrrr.

[pwal] 14/11/2022 09:15

Let's hope it continues.

[maverick67] 14/11/2022 09:06

Bit of buying today.... Leaked news??

[clocktower] 02/11/2022 11:31

Nobby, You should give the male directors of MIN any spare Viagra you have laying around, as you had a keen interest in that molecule, it might help them and you to get it up. :-)

[jakleeds] 02/11/2022 09:13

Hello what’s happening here ??

[nobbygnome] 02/11/2022 08:07

Read back on my comments on the science and you will find a lot more than vague insinuations.

My doubts started way back with the Viagra look alike and I was proved to be 100% correct. I should say that my wife was involved from a marketing point of view with the launch of Viagra with Pfizer so I also had a keen interest in that molecule from a scientific perspective.